Person: Antón Rodríguez, Cristina
Loading...
First Name
Cristina
Last Name
Antón Rodríguez
Affiliation
Faculty
Medicina
Department
Area
Identifiers
16 results
Search Results
Now showing 1 - 10 of 16
Item Evaluation of learning outcomes of humanities curricula in medical students. A meta-review of narrative and systematic reviews.(Frontiers in Medicine, 2023) Coronado Vázquez, Valle; Antón Rodríguez, Cristina; Gómez-Salgado, Juan; Ramírez-Durán, Mª del Valle; Álvarez-Montero, SantiagoObjectives: To assess the expected learning outcomes of medical humanities subjects in medical studies curricula. To connect those expected learning outcomes with the types of knowledge to be acquired in medical education. Methods: Meta-review of systematic and narrative reviews. Cochrane Library, MEDLINE (Pubmed), Embase, CINAHL, and ERIC were searched. In addition, references from all the included studies were revised, and the ISI Web of Science and DARE were searched. Results: A total of 364 articles were identified, of which six were finally included in the review. Learning outcomes describe the acquisition of knowledge and skills to improve the relationship with patients, as well as the incorporation of tools to reduce burnout and promote professionalism. Programs that focus on teaching humanities promote diagnostic observation skills, the ability to cope with uncertainty in clinical practice, and the development of empathetic behaviors. Conclusion: The results of this review show heterogeneity in the teaching of medical humanities, both in terms of content and at the formal level. Humanities learning outcomes are part of the necessary knowledge for good clinical practice. Consequently, the epistemological approach provides a valid argument for including the humanities in medical curricula.Item Indicators to evaluate quality of care in head and neck cancer in Spain.(Clinical and Translational Oncology, 2023) Cruz Hernández, Juan Jesús; Campos Lucas, Francisco Javier; Caballero Martínez, Fernando; Monge Martín, Diana; Antón Rodríguez, CristinaPurpose This study aimed to develop a set of criteria and indicators to evaluate the quality of care of patients with head and neck cancer (HNC). Methods A systematic literature review was conducted to identify valuable criteria/indicators for the assessment of the quality of care in HNC. With the aid of a technical group, a scientific committee of oncologists specialised in HNC used selected criteria to propose indicators that were evaluated with a two-round Delphi method. Indicators on which consensus was achieved were then prioritised by the scientific committee to develop a final set of indicators. Results We proposed a list of 50 indicators used in the literature or developed by us to be evaluated with a Delphi method. There was consensus on the appropriateness of 47 indicators in the first round; the remaining 3 achieved consensus in the second round. The 50 indicators were scored to prioritise them, leading to a final selection of 29 indicators related to structure (3), process (22), or outcome (4) and covering diagnosis, treatment, follow-up, and health outcomes in patients with HNC. Easy-to-use index cards were developed for each indicator, with their criterion, definition, formula for use in real-world clinical practice, rationale, and acceptable level of attainment. Conclusions We have developed a set of 29 evidence-based and expert-supported indicators for evaluating the quality of care in HNC, covering diagnosis, treatment, follow-up, and health outcomes.Item PrediCTC, liquid biopsy in precision oncology: a technology transfer experience in the Spanish health system.(Clinical and Translational Oncology, 2017) Alonso Alconada, Lorena; Barbazan, Jorge; Candamio, Sonia; Falco, Josep Lluis; Antón Rodríguez, Cristina; Martín Saborido, Carlos; Fuster, Gustavo; Sampedro, Mabel; Grande, Carlos; Lado, Rubén; Sampietro Colom, Laura; Crego, Eladio; Figueiras, Sergio; León Mateos, Luis; López López, Rafael; Abal, MiguelPurpose: Management of metastatic disease in oncology includes monitoring of therapy response principally by imaging techniques like CT-Scan. In addition to some limitations, the irruption of liquid biopsy and its application in personalized medicine has encouraged the development of more efficient technologies for prognosis and follow-up of patients in advanced disease. Methods: PrediCTC constitutes a panel of genes for the assessment of Circulating Tumor Cells (CTC) in metastatic colorectal cancer patients, with demonstrated improved efficiency compared to CT-Scan for the evaluation of early therapy response in a multicenter prospective study. In this work, we designed and developed a technology transfer strategy to define the market opportunity for an eventual implementation of PrediCTC in the clinical practice. Results: This included the definition of the regulatory framework, the analysis of the regulatory roadmap needed for CE mark, a benchmarking study, the design of a product development strategy, a revision of intellectual property, a cost-effectiveness study and an expert panel consultation. Conclusion: The definition and analysis of an appropriate technology transfer strategy and the correct balance among regulatory, financial and technical determinants are critical for the transformation of a promising technology into a viable technology, and for the decision of implementing liquid biopsy in the monitoring of therapy response in advanced disease.Item Evaluación del estado nutricional al ingreso y evolución tras siete días de hospitalización en un hospital de segundo nivel de Madrid.(Nutrición Hospitalaria, 2021) Villaverde Núñez, Alberto; Pérez Ramos, Cristina; Sanz Lobo, María Victoria; Morgado Benito, María del Carmen; Martínez-Ibáñez, Virginia; Avecilla Nieto, Noelia; Antón Rodríguez, CristinaIntroducción: la desnutrición hospitalaria es un problema de alta prevalencia y continúa siendo a día de hoy una asignatura pendiente, ya que a menudo pasa desapercibida para el personal sanitario, con las consiguientes repercusiones clínicas negativas que esto conlleva. Objetivos: a) evaluar el estado nutricional al ingreso; b) conocer la evolución tras una semana de hospitalización; c) analizar la relación entre el estado nutricional y distintas variables clínicas (especialidades, edad, pérdida de peso corporal, estancia media, reingresos e interconsultas al servicio de endocrinología-nutrición). Métodos: estudio observacional, prospectivo, analítico y aleatorio de 260 pacientes de servicios médicos y quirúrgicos, evaluados nutricionalmente al ingreso y tras siete días de hospitalización mediante la VGS y la NRS-2002. Resultados: la prevalencia al ingreso según la VGS fue del 48 % y según la NRS-2002 del 38,5 %. Tras una semana de hospitalización, la prevalencia aumentó al 72,5 % y el 58,8 %, respectivamente. Tras siete días, en el 2-7,8 % mejoró el estado nutricional; en cambio, en el 16-27,5 % empeoró. La desnutrición al ingreso se asoció con estancias más prolongadas (6 días los normonutridos frente a 8 días los desnutridos); con una mayor edad (64 años los normonutridos frente a 71 años los desnutridos); con las especialidades médicas más que con las quirúrgicas (44-53 % vs. 20-32 %); con la pérdida de peso (al ingresar habían perdido 2,1 kg de media respecto al peso habitual y 0,9 kg tras siete días de hospitalización); y con los reingresos prematuros (8-11 % los normonutridos frente a 27 % los desnutridos), entre otros. Conclusiones: los resultados hallados nos ofrecen una panorámica de la desnutrición hospitalaria, mostrando cómo evolucionan nutricionalmente los pacientes durante los ingresos y cuáles son los momentos cruciales de actuación. Es sumamente importante que el personal sanitario se conciencie y tome medidas.Item The caregiver’s perspective on end-of-life inpatient palliative care: a qualitative study.(Annals of Medicine, 2023) Herrera-Abiána, María; Castañeda-Vozmediano, Raul; Antón Rodríguez, Cristina; Palacios-Ceña, Domingo; González-Morales, Luz María; Pfang, Bernadette; Noguera, AntonioIntroduction: Understanding patient and caregiver experience is key to providing person-centered care. The palliative care approach includes holistic assessment and whole-person care at the end of life, that also involves the patient’s family and loved ones. The aim of this study was to describe the way that family caregivers experienced patients’ deaths during their loved ones’ last hospital admission, comparing inpatient palliative care (PCU) and non-palliative care (Non-PCU) units. Methods: A qualitative case study approach was implemented. Family caregivers of terminally ill patients admitted to the Infanta Elena Hospital (Madrid, Spain) between 2016 and 2018 were included using purposeful sampling. Eligible caregivers were first-degree relatives or spouses present during the patient’s last hospital admission. Data were collected via in-depth interviews and researchers’ field notes. Semi-structured interviews with a question guide were used. A thematic inductive analysis was performed. The group of caregivers of patients admitted to the PCU unit and the group of caregivers of patients admitted to Non-PCU were analyzed separately, through a matrix. Results: In total 24 caregivers (12 from the PCU and 12 from Non-PCU units) were included. Two main themes were identified: caregivers’ perception of scientific and technical appropriateness of care, and perception of person-centred care. Scientific appropriateness of care was subdivided into two categories: diagnostic tests and treatment, and symptom control. Perception of person-centred care was subdivided as: communication, emotional support, and facilitating the farewell process. Caregivers of patients admitted to a PCU unit described their experience of end-of-life care as positive, while their Non-PCU unit counterparts described largely negative experiences. Conclusions: PCU provides a person-centered approach to care at the end of life, optimizing treatment for patients with advanced disease, ensuring effective communication, establishing a satisfactory professional relationship with both patients and their loved ones, and facilitating the farewell process for family caregivers.Item Economic Evaluation of Fluticasone Propionate/ Formoterol (Flutiform ) vs. Fluticasone/Salmeterol and Budesonide/Formoterol in Spain.(Pulmonary Therapy, 2016-10-17) Martínez-Moragón, Eva; Delgado, Julio; Ojeda, Pedro; Pérez del Llano, Luis; Collar, Juan Manuel; Antón Rodríguez, Cristina; Martín Saborido, CarlosIntroduction: The aim of this economic evaluation was to estimate the cost-effectiveness of fluticasone propionate/formoterol (FP/FORM; Flutiform ) and compare it to those of fluticasone/ salmeterol (FS) and budesonide/formoterol (BF) when used in the treatment of adult patients with moderate-to-severe asthma. Methods: A Markov model was developed with five asthma health states: successful control, suboptimal control, outpatient-managed exacerbation, inpatient-managed exacerbation, and death. The time horizon was set at 12 months. Transition probabilities and indirect resource utilization were derived from previous international and Spanish publications. Univariate and probabilistic sensitivity analyses (SAs) were applied. Results: FP/FORM was less expensive to acquire than FS or BF (20% lower than FS and 30% lower than BF), while the quality-adjusted life years (QALYs) of the three options compared were very similar. Cost per patient in the FP/FORM cohort was 9326€/year, making it the cheapest option, 1.5% cheaper than FS and 2.6% cheaper than BF. The suboptimal control health state dominated the costs (80% of the total cost) in each of the analyzed options and scenarios. The results of the SAs verified the data obtained from the base case scenario. Conclusions: From a Spanish societal perspective, in 2014, FP/FORM produced a similar gain in QALYs but at a lower cost when compared to FS and BF in a highly meaningful number of replications and scenarios. FP/FORM can therefore be considered a cost-effective option in the treatment of moderate-to-severe asthma in Spain. The cost savings were mainly due to the significantly lower acquisition cost of FP/FORM than the other two options.Item End of Life Cost Savings in the Palliative Care Unit Compared to Other Services.(Journal of Pain and Symptom Management, 2022) Herrera Abián, María; Antón Rodríguez, Cristina; Noguera, AntonioContext Hospital deaths carry a significant healthcare cost that has been confirmed to be lower when palliative care units (PCUs) are available. Objectives To compare the last admission hospital health care cost of dying in a first-level hospital between the PCU and the rest of the hospital services. Methods A retrospective, comparative, observational study evaluating costs from the payer perspective on treatments and diagnostic-therapeutic tests performed on patients who die in first-level hospital, comparing whether they were treated by the PCU or another unit (Non-PCU). Patients with a mortality risk >2 were included according to the Severity of Illness Index (SOI) and Risk of Mortality (MOR). All cost express in €, median per patient and interquartile range (IQR). Results From 1,833 patients who died, 1,389 were included, 442 (31.1%) treated by PCU and 928 (68.9%) Non-PCU. Statistical differences were found for the last admission total cost (€262.8 (€470.1) for PCU versus €515.3 (€980.48) in Non-PCU), daily total cost (€74.27 (€127.4) vs €115.8 (€142.4) Non-PCU). Savings were maintained when the sample was broken down by diagnosis-related group (DRG) and a multivariate analysis was performed to determine how the different patients baseline characteristics between PCU and Non-PCU patients influenced the results obtained. Conclusions Data from this study show that cost is significantly lower when the patients are treated by a PCU during their last hospital stay when they pass away.Item Cost Effectiveness of Quadrivalent Versus Trivalent Inactivated Influenza Vaccines for the Portuguese Elderly Population.(Vaccines, 2022) Tavares, Diana; Mouriño, Helena; Antón Rodríguez, Cristina; Martín Saborido, CarlosBackground: quadrivalent inactivated vaccine (QIV) has replaced trivalent inactivated vaccine (TIV). In Portugal, TIV is free of charge for risk groups, including older adults (≥65 years old). In its turn, QIV—which provides broader protection as it includes an additional lineage B strain—was introduced in Portugal in October 2018; only since the 2019/20 influenza season has it been provided free of charge for risk groups. This study evaluates the cost effectiveness of switching from TIV to QIV, from the National Health Service perspective, in the Portuguese elderly mainland population. Methods: A decision tree model was developed to compare TIV and QIV, based on Portuguese hospitalization data for the 2015/16 influenza season. The primary health economic outcome under consideration was the incremental cost-effectiveness ratio (ICER). In addition, one-way sensitivity analysis and probabilistic sensitivity analysis were performed. Results: the high cost of QIV (approximately three times the cost of TIV) would lead to a total increment of EUR 5,283,047, and the resulting ICER would be EUR 26,403,007/QALY, above the usual willingness-to-pay threshold. Conclusions: from the National Health Service perspective, our findings reveal that QIV is not cost effective for the Portuguese elderly population due to the high cost. If the QIV costs were the same as the TIV, then QIV would be cost effective.Item Effect of the SARS-CoV-2 pandemic on the control and severity of pediatric asthma.(Allergologia et immunopathologia, 2022) Sánchez-García, Silvia; Ruiz Hornillos, Francisco Javier; Bernaola, Marta; Habernau-Menaf, Alicia; Lasa, Eva María; Contreras, Javier; Candón-Morillo, Rocío; Antón Rodríguez, Cristina; Escudero, CarmeloBackground: The novel disease caused by the new coronavirus SARS-CoV-2 has caused an unprecedented global pandemic. Care providers of asthmatic children are increasingly con-cerned; as viral infections are one of the primary triggers of asthma flare-up. However, the effect of SARS-CoV-2 as well as the generated worldwide lockdown on asthmatic children is unknown. Objective: The aim of this study was to analyze the effects of pandemic SARS-CoV-2 in pediat-ric asthma control. Material and Methods: A retrospective, open, transversal study was performed at five ter-tiary hospitals. Recruited patients were aged <18 years and had physician-diagnosed asthma. Information regarding the 2019 and 2020 seasons were provided. Results: Data were collected from 107 children (age range: 3–18 years, mean age: 12 years). Well-controlled asthma was observed in 58 (54.2%) patients in 2020 versus 30 (28%) in 2019, and 15 (14%) patients had poorly controlled asthma in 2020 versus 28 (26.2%) in 2019. In 2020, a decrease in exacerbations caused by allergies to pollen, dust mites, molds, and through other causes not related to SARS-CoV-2 infection was observed. An increase in exacerbations was observed due to animal dander, stress, physical exercise, and SARSCoV- 2 infectionItem Randomised multicentre clinical trial to evaluate voriconazole pre-emptive genotyping strategy in patients with risk of aspergillosis: vorigenipharm study protocol.(BMJ Open, 2020) Monserrat Villatoro, Jaime; García García, Irene; Bueno, David; De la Cámara, Rafael; Estébanez, Miriam; López de la Guía, Ana; Abad-Santos, Francisco; Antón Rodríguez, Cristina; Mejía, Gina; Otero, María José; Ramírez García, Elena; Frías Iniesta, Jesús; Carcas, Antonio; Borobia, Alberto M.Introduction Invasive aspergillosis is the most important cause of morbidity and mortality in patients with haematological diseases. At present, voriconazole is the first-line treatment for invasive fungal disease. The pharmacokinetic interindividual variability of voriconazole depends on genetic factors. CYP450 is involved in 70%–75% of total metabolism of voriconazole, mainly CYP3A4 and CYP2C19, with the remaining 25%–30% of metabolism conducted by monooxygenase flavins. CYP2C19 single nucleotide polymorphisms could explain 50%–55% of variability in voriconazole metabolism. Materials and methods The main objective is to compare efficiency of pre-emptive voriconazole genotyping with routine practice. The primary outcome is serum voriconazole on the fifth day within the therapeutic range. The secondary outcome is the combined variables of therapeutic failure and adverse events within 90 days of first administration, associated with voriconazole. A total of 146 patients at risk of invasive aspergillosis who will potentially receive voriconazole will be recruited, and CYP2C19 will be genotyped. If the patient ultimately receives voriconazole, they will be randomised (1:1 experimental/control). In the experimental arm, patients will receive a dose according to a pharmacogenetic algorithm, including CYP2C19 genotype and clinical and demographic information. In the control arm, patients will receive a dose according to clinical practice guidelines. In addition, a Spanish National Healthcare System (NHS) point-of-view cost-effectiveness evaluation will be performed. Direct cost calculations for each arm will be performed. Conclusion This trial will provide information about the viability and cost-effectiveness of the mplementation of a pre-emptive voriconazole genotyping strategy in the Spanish NHS. Ethics and dissemination A Spanish version of this protocol has been evaluated and approved by the La Paz University Hospital Ethics Committee and the Spanish Agency of Medicines and Medical Devices. Trial results will be submitted for publication in an open peer-reviewed medical speciality-specific publication. Trial registration number Eudra-CT: 2019-000376-41 and NCT04238884; Pre-results.